TVRD Stock Price, Chart, Stats & News
Tvardi Therapeutics, Inc. (TVRD) does not currently pay a dividend.
TVRD chart
Fundamentals
Gross margin | 97.79% |
Operating margin | -576.39% |
Pretax margin | -356.44% |
Net margin | -346.55% |
Effective tax rate | 2.77% |
ROA | -35.74% |
ROE | -135.79% |
D/E | 0.01x |
Interest coverage ratio | -4.23x |
TVRD valuation
P/E | – |
P/S | 7.39x |
P/B | 1.07x |
P/CF | -1.36x |
P/FCF | -1.36x |
P/OCF | -1.36x |
PEG | -0.04x |
EV multiple | -2.33x |
About
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Similar securities
Based on sector and market capitalization
